Abstract:Dear editor: Recent articles in this Journal have reported the cross-neutralization of SARS-CoV-2 variants in individuals of vaccinees and convalescents, and compared the clinical features of Coronavirus disease 2019 (COVID-19) by SARS-CoV-2 Gamma variant based on a prospective cohort study of vaccinated and unvaccinated healthcare workers1Gidari A. et al.Cross-neutralization of SARS-CoV-2 B1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.J Infect. 2021; 83: 467-472https://doi.org/10.1016/j.jinf.2021.07.019Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar,2Luna-Muschi A. et al.Clinical features of COVID-19 by SARS-CoV-2 Gamma variant: a prospective cohort study of vaccinated and unvaccinated healthcare workers.J Infect. 2021; https://doi.org/10.1016/j.jinf.2021.09.005Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar. The emergence of SARS-CoV-2 variants with higher transmission ability and immune evasion against monoclonal antibodies, sera from natural infection and vaccine receipts, posing a serious threat to public health. On 26 November 2021, the World Health Organization named the new SARS-CoV-2 variant B.1.1.529 as Omicron, and defined it as a Variant of Concern (VOC). As the fifth VOCs currently, Omicron contains much more mutations in the Spike protein, including some mutations shown to reduce neutralizing efficiencies of COVID-19 vaccines in previous studies3Tao K. et al.The biological and clinical significance of emerging SARS-CoV-2 variants.Nat Rev Genet. 2021; 22: 757-773https://doi.org/10.1038/s41576-021-00408-xCrossref PubMed Scopus (180) Google Scholar. As the pandemic of COVID-19 has lasted for nearly two years, there are more and more convalescents either previously infected with wild-type SARS-CoV-2 or recently emerged variants. Meanwhile, booster vaccination of SARS-CoV-2 is now rapidly rolling out in China and other countries. Accordingly, neutralizing efficiency of convalescents and vaccinees with booster vaccination against the newly emerged Omicron variant needs further elucidation. Here we evaluated the neutralizing activity of plasma from the COVID-19 convalescents with wild type SARS-CoV-2 and different VOCs, and vaccinees with both regular vaccination and homologous booster of inactivated vaccine. A total of 92 participants were included in this study, including 24 vaccinees with homologous booster vaccination (Vaccinee group), 26 individuals previously infected with wild type (WT) SARS-CoV-2 (WT group), 16 patients infected with Alpha variant (Alpha group, 12 patients received vaccination before infection), 6 patients infected with Beta variant (Beta group), and 20 patients infected with Delta variant (Delta group, 4 patients received vaccination before infection). All the individuals with breakthrough infection received at least one-dose inactivated vaccines (CoronaVac or BBIBP-CorV before laboratory confirmation of infection, and individuals in the vaccinee group received inactivated vaccines (BBIBP-CorV) and homologous booster vaccination. The detailed information was shown in Table S1. All the plasma samples in the WT group were collected over 386 days post illness onset/laboratory confirmation (median: 431.5; range: 386–471), and most samples (40/42, 95.23%) in the Alpha, Beta, Delta groups were collected over 7 days after laboratory confirmation (median: 18; range: 1–36). Samples from the vaccinee group were collected after the two dose of vaccination with median days of 85 (range: 28–103), and 95 days after booster vaccination. For the WT group, about 46.15% (12/26) of the samples showed inhibition rates over 50% against Omicron variant at the first dilution (1:20). The geometric mean neutralizing titers (GMTs) against wild type SARS-CoV-2 (WT) and Omicron variant were 154.07 (54.64 to 1018.82), 22.96 (10 to 145.38), respectively, and the reduction fold was 6.71 for Omicron (Fig. 1A). This reduction is comparable with Mu variant while higher than Alpha, Beta, Gamma, Delta, Lambda variants4Yang; Y et al.Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.Nature Mocribiol. 2021; 6Google Scholar. For the Alpha group, all the samples from breakthrough infections showed detectable 50% inhibitory dose (ID50) against Omicron variant, while 50% (2/4) were below the lower limit of quantitation in the naive infections. The overall GMTs against Alpha and Omicron variants were 7198.43 and 285 respectively, with 25.26-fold reduction for the Omicron variant (Fig. 1B). Comparison between breakthrough and naive infection showed significantly higher ID50 against both Alpha (9.33-fold) and Omicron variants (5.61-fold) in the breakthrough infection (Fig. 1B). Similar results were found in the Delta group, with all the samples from breakthrough infection showed detectable ID50 against Omicron variant, while 1 out of 16 was below the lower limit of quantitation in the naive infection. The overall GMTs against Delta and Omicron variants were 10,898.97 and 558.44, respectively, with 19.52-fold reduction for the Omicron variant (Fig. 1D). Significantly higher ID50 against both Delta (3.25-fold) and Omicron variants (1.77-fold) were also found in the breakthrough infections (Fig. 1D). For the Beta group, we only got the naive infections, and reduced neutralizing activities were also found with 18.38-fold reduction against the Omicron variant (Fig. 1C). In the Vaccinee group, 91.66 (22/24) showed detectable ID50 against wild type SARS-CoV-2 at 95 days post booster vaccination with GMT of 299, and 1.67-fold, 14.52-fold, 3.72-fold and 6.73-fold reduction against Alpha, Beta, Gamma and Delta variants were found, respectively (Fig. 2A). Notably, only 25% (6/24) of the samples showed detectable ID50 against Omicron, with 16.07-fold reduction when compared with wild type SARS-CoV-2. We further compared the neutralization activity before and after booster vaccination against different VOCs. After booster vaccination, GMTs against wild type, Alpha, Beta, Gamma, Delta increased 13.47-fold, 8.63-fold, 2.06-fold, 6.75-fold and 3.96 fold, respectively (Fig. 2B). For the Omicron variant, all samples were below the lower limit of quantitation after the first two dose vaccination, similar with previous study5Lu L. et al.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.Clin Infect Dis. 2021; https://doi.org/10.1093/cid/ciab1041Crossref Google Scholar. However, 6 out of 24 (25%) showed detectable ID50 (GMT: 18.62; range: 10 to 454.4) after booster vaccination, with 1.86-fold increase in GMTs (Fig. 2B). Although some recent studies have showed that Omicron variant could escape from the majority of existing SARS-CoV-2 neutralizing antibodies6Cao Y et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.Nature. 2021; 585Google Scholar and vaccine induced immune response5Lu L. et al.Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients.Clin Infect Dis. 2021; https://doi.org/10.1093/cid/ciab1041Crossref Google Scholar, our study still provide unique information as follows. Firstly, we addressed whether COVID-19 convalescents previously infected with wild type SARS-CoV-2 could provide protection against Omicron Variant even after one year. Secondly, we used paired samples with both regular vaccination and homologous booster vaccination to evaluated the efficiency of booster vaccination. Thirdly, we compared the neutralizing activities against Omicron variant between breakthrough and naive infections with different VOCs. Similar with previous studies, significant immune evasion was found for Omicron variant both in the convalescents and vaccinees, and the reduction folds was even higher than the previously least susceptible Beta and Mu variants4Yang; Y et al.Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.Nature Mocribiol. 2021; 6Google Scholar,7Uriu K. et al.Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum.N Engl J Med. 2021; 385: 2397-2399https://doi.org/10.1056/NEJMc2114706Crossref PubMed Scopus (51) Google Scholar, suggesting a higher risk of breakthrough infection or reinfection. It is worth noting that plasma samples collected over one year post infection showed lower reduction folds against Omicron variant when compared with other convalescents with different VOCs, which might correlate with the increase in the breadth and potency of SARS-CoV-2 specific antibodies due to the maturation of memory B cells8Muecksch F. et al.Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.Immunity. 2021; 54 (1853-1868.e1857)https://doi.org/10.1016/j.immuni.2021.07.008Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 9Sokal A. et al.Maturation and persistence of the anti-SARS-CoV-2 memory B cell response.Cell. 2021; 184 (1201-1213.e1214)https://doi.org/10.1016/j.cell.2021.01.050Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar, 10Wang Z. et al.Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.Nature. 2021; 595: 426-431https://doi.org/10.1038/s41586-021-03696-9Crossref PubMed Scopus (217) Google Scholar. Despite of the obvious immune evasion, our study also confirmed the importance of vaccination, both regular and booster vaccination. As shown in our study, breakthrough infections developed much higher neutralizing antibodies than the naive infection, both against the infected variant and Omicron variant. Moreover, booster vaccination could significantly increase the neutralizing responses to all the VOCs, although lower neutralizing abilities were found against some VOCs. Therefore, active vaccination still serve as one of the most effective measures to control the pandemic of COVID-19, and new vaccines with higher protective efficiency are also in urgent need. This work was supported by grants from National Natural Science Foundation of China ( 32170936 ), National Science and Technology Major Project ( 2021YFC0863300, 2021YFC2301800 ). The authors wish to thank the biological sample bank of the Shenzhen Third People's Hospital for bio-samples and services provided.

Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources

Neutralizing Activity of SARS-CoV-2 Antibodies in Patients with COVID-19 and Vaccinated Individuals

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

COVID-19-neutralizing antibodies predict disease severity and survival

COVID-19 neutralizing antibodies predict disease severity and survival

Neutralization Against SARS-CoV-2 Delta/Omicron Variants and B Cell Response after Inactivated Vaccination among COVID-19 Convalescents

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum

Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum

SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

Resistance of SARS-CoV-2 Omicron Variant to Convalescent and CoronaVac Vaccine Plasma

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Comparison of Neutralizing Activity between Vaccinated and Unvaccinated Hospitalized COVID-19 Patients Infected with Delta, Omicron BA.1, or Omicron BA.2 Variant

Regular and Booster Vaccination with Inactivated Vaccines Enhance the Neutralizing Activity Against Omicron Variant Both in the Breakthrough Infections and Vaccinees

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant

Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination

Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis

Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination